Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation Oncology | 15 | 2022 | 19 | 4.910 |
Why?
|
Brain Neoplasms | 14 | 2022 | 301 | 3.970 |
Why?
|
Radiosurgery | 9 | 2021 | 84 | 3.210 |
Why?
|
Meningeal Neoplasms | 6 | 2021 | 73 | 3.020 |
Why?
|
Meningioma | 6 | 2018 | 79 | 2.430 |
Why?
|
Publications | 4 | 2018 | 24 | 2.280 |
Why?
|
Internship and Residency | 7 | 2021 | 239 | 2.250 |
Why?
|
Radiotherapy | 6 | 2021 | 41 | 1.950 |
Why?
|
Career Choice | 5 | 2020 | 53 | 1.850 |
Why?
|
Neurosurgical Procedures | 5 | 2021 | 217 | 1.820 |
Why?
|
Medical Oncology | 4 | 2025 | 93 | 1.590 |
Why?
|
Humans | 80 | 2025 | 27968 | 1.440 |
Why?
|
Radiation Oncologists | 7 | 2020 | 7 | 1.350 |
Why?
|
Practice Patterns, Physicians' | 7 | 2020 | 163 | 1.280 |
Why?
|
Lung Neoplasms | 8 | 2020 | 353 | 1.220 |
Why?
|
United States | 18 | 2025 | 2139 | 1.120 |
Why?
|
African Americans | 3 | 2018 | 352 | 1.090 |
Why?
|
Databases, Factual | 4 | 2021 | 253 | 1.080 |
Why?
|
Neuroma, Acoustic | 2 | 2017 | 23 | 1.080 |
Why?
|
Glioblastoma | 4 | 2020 | 105 | 0.980 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 330 | 0.980 |
Why?
|
Male | 33 | 2025 | 13424 | 0.950 |
Why?
|
Combined Modality Therapy | 10 | 2022 | 297 | 0.920 |
Why?
|
Private Practice | 4 | 2021 | 8 | 0.910 |
Why?
|
Bibliometrics | 3 | 2018 | 19 | 0.870 |
Why?
|
Muscle Proteins | 2 | 2015 | 56 | 0.870 |
Why?
|
Aged | 19 | 2021 | 5383 | 0.860 |
Why?
|
Female | 32 | 2025 | 15074 | 0.840 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 37 | 0.810 |
Why?
|
Nerve Tissue Proteins | 2 | 2015 | 152 | 0.810 |
Why?
|
Melanoma | 2 | 2021 | 140 | 0.790 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 407 | 0.790 |
Why?
|
Authorship | 2 | 2018 | 14 | 0.750 |
Why?
|
Peer Review, Research | 2 | 2018 | 9 | 0.730 |
Why?
|
Spinal Neoplasms | 2 | 2020 | 39 | 0.720 |
Why?
|
Astrocytoma | 1 | 2021 | 35 | 0.720 |
Why?
|
Autophagy | 4 | 2009 | 73 | 0.710 |
Why?
|
Prostatic Neoplasms | 4 | 2017 | 277 | 0.710 |
Why?
|
Education, Medical, Graduate | 2 | 2018 | 108 | 0.710 |
Why?
|
Glioma | 1 | 2022 | 117 | 0.700 |
Why?
|
Lymphoma | 1 | 2020 | 25 | 0.700 |
Why?
|
Whole-Body Irradiation | 1 | 2020 | 40 | 0.700 |
Why?
|
Middle Aged | 21 | 2021 | 7111 | 0.690 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 105 | 0.680 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 120 | 0.680 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 248 | 0.680 |
Why?
|
Students, Medical | 2 | 2018 | 96 | 0.670 |
Why?
|
Healthcare Disparities | 1 | 2021 | 90 | 0.670 |
Why?
|
Germinoma | 1 | 2019 | 4 | 0.650 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 13 | 0.640 |
Why?
|
Neoplasms | 5 | 2021 | 803 | 0.640 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2010 | 546 | 0.620 |
Why?
|
Health Policy | 1 | 2019 | 61 | 0.620 |
Why?
|
Anterior Temporal Lobectomy | 1 | 2018 | 1 | 0.610 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 2018 | 4 | 0.610 |
Why?
|
Wireless Technology | 1 | 2018 | 2 | 0.610 |
Why?
|
Adenocarcinoma | 3 | 2010 | 297 | 0.610 |
Why?
|
Magnetic Field Therapy | 1 | 2018 | 3 | 0.600 |
Why?
|
Financing, Personal | 1 | 2018 | 4 | 0.600 |
Why?
|
Apoptosis | 7 | 2015 | 772 | 0.600 |
Why?
|
Cell Phone | 1 | 2018 | 20 | 0.600 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 60 | 0.590 |
Why?
|
Patient Safety | 1 | 2018 | 38 | 0.590 |
Why?
|
Neurosurgery | 4 | 2021 | 75 | 0.580 |
Why?
|
Receptor, trkB | 4 | 2012 | 6 | 0.570 |
Why?
|
Lymphocytes | 1 | 2018 | 90 | 0.570 |
Why?
|
Ventral Thalamic Nuclei | 1 | 2017 | 1 | 0.570 |
Why?
|
Essential Tremor | 1 | 2017 | 2 | 0.570 |
Why?
|
Spinal Cord Compression | 1 | 2017 | 20 | 0.560 |
Why?
|
Deep Brain Stimulation | 1 | 2017 | 7 | 0.560 |
Why?
|
Retrospective Studies | 12 | 2022 | 2541 | 0.560 |
Why?
|
Ambulatory Care | 1 | 2017 | 60 | 0.550 |
Why?
|
Insurance Coverage | 1 | 2017 | 31 | 0.540 |
Why?
|
Efficiency | 5 | 2021 | 17 | 0.530 |
Why?
|
Medulloblastoma | 1 | 2016 | 18 | 0.530 |
Why?
|
Prognosis | 7 | 2021 | 802 | 0.530 |
Why?
|
Palliative Care | 1 | 2017 | 82 | 0.520 |
Why?
|
Follow-Up Studies | 5 | 2021 | 1011 | 0.500 |
Why?
|
Neuroblastoma | 4 | 2005 | 56 | 0.500 |
Why?
|
Adult | 12 | 2021 | 7703 | 0.490 |
Why?
|
Stroke | 1 | 2018 | 249 | 0.470 |
Why?
|
Brain-Derived Neurotrophic Factor | 3 | 2005 | 22 | 0.470 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 103 | 0.460 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2020 | 14 | 0.460 |
Why?
|
Magnetic Resonance Imaging | 5 | 2020 | 817 | 0.440 |
Why?
|
Child | 6 | 2021 | 2225 | 0.400 |
Why?
|
Neovascularization, Pathologic | 2 | 2013 | 149 | 0.400 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2012 | 44 | 0.390 |
Why?
|
Treatment Outcome | 6 | 2020 | 2367 | 0.390 |
Why?
|
Cell Line, Tumor | 9 | 2018 | 1314 | 0.380 |
Why?
|
Breast Neoplasms | 3 | 2021 | 458 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 194 | 0.360 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2012 | 461 | 0.360 |
Why?
|
Protein Kinases | 3 | 2012 | 148 | 0.350 |
Why?
|
Enzyme Inhibitors | 4 | 2013 | 249 | 0.340 |
Why?
|
Central Nervous System Diseases | 2 | 2021 | 13 | 0.340 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2010 | 13 | 0.340 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2021 | 25 | 0.330 |
Why?
|
Ferrosoferric Oxide | 2 | 2020 | 5 | 0.330 |
Why?
|
Surveys and Questionnaires | 8 | 2025 | 967 | 0.330 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 9 | 0.320 |
Why?
|
Survival Rate | 4 | 2021 | 428 | 0.310 |
Why?
|
Radiation | 1 | 2009 | 3 | 0.310 |
Why?
|
Molecular Biology | 1 | 2009 | 17 | 0.310 |
Why?
|
Chemoradiotherapy | 2 | 2019 | 44 | 0.300 |
Why?
|
Seminoma | 2 | 2018 | 2 | 0.300 |
Why?
|
Spinal Cord Neoplasms | 2 | 2020 | 35 | 0.300 |
Why?
|
Testicular Neoplasms | 2 | 2018 | 16 | 0.290 |
Why?
|
Radiotherapy Dosage | 4 | 2023 | 104 | 0.290 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 41 | 0.290 |
Why?
|
Watchful Waiting | 2 | 2018 | 18 | 0.290 |
Why?
|
Sirolimus | 2 | 2008 | 76 | 0.290 |
Why?
|
Signal Transduction | 6 | 2013 | 1433 | 0.280 |
Why?
|
Child, Preschool | 3 | 2021 | 1133 | 0.280 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 225 | 0.260 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 65 | 0.260 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 225 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2005 | 135 | 0.260 |
Why?
|
Tumor Microenvironment | 2 | 2025 | 176 | 0.240 |
Why?
|
Immunoblotting | 3 | 2015 | 124 | 0.240 |
Why?
|
Cisplatin | 2 | 2003 | 179 | 0.240 |
Why?
|
Carboplatin | 3 | 2019 | 111 | 0.230 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2025 | 36 | 0.230 |
Why?
|
Disease-Free Survival | 2 | 2016 | 237 | 0.230 |
Why?
|
Hybrid Cells | 2 | 2021 | 8 | 0.220 |
Why?
|
Cell Movement | 3 | 2015 | 365 | 0.220 |
Why?
|
Neoplasm Staging | 5 | 2018 | 478 | 0.210 |
Why?
|
Animals | 12 | 2025 | 10370 | 0.200 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2002 | 26 | 0.200 |
Why?
|
Benzamides | 1 | 2002 | 34 | 0.200 |
Why?
|
Radiology | 1 | 2022 | 20 | 0.200 |
Why?
|
Cell Proliferation | 3 | 2015 | 802 | 0.200 |
Why?
|
Radiation-Sensitizing Agents | 3 | 2013 | 32 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 163 | 0.190 |
Why?
|
Pyridines | 1 | 2002 | 106 | 0.190 |
Why?
|
Carcinoma, Renal Cell | 1 | 2022 | 77 | 0.190 |
Why?
|
Tumor Burden | 2 | 2019 | 110 | 0.180 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 101 | 0.180 |
Why?
|
Antineoplastic Agents | 3 | 2009 | 679 | 0.180 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 112 | 0.180 |
Why?
|
Peer Review | 1 | 2020 | 14 | 0.180 |
Why?
|
Population Surveillance | 2 | 2018 | 86 | 0.170 |
Why?
|
Societies, Medical | 1 | 2021 | 92 | 0.170 |
Why?
|
Prevalence | 2 | 2020 | 496 | 0.170 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2013 | 251 | 0.170 |
Why?
|
Radiotherapy, Conformal | 1 | 2020 | 15 | 0.170 |
Why?
|
Ependymoma | 1 | 2020 | 11 | 0.170 |
Why?
|
Cell Cycle | 3 | 2012 | 161 | 0.170 |
Why?
|
American Recovery and Reinvestment Act | 1 | 2019 | 3 | 0.160 |
Why?
|
Carcinoma, Large Cell | 1 | 2019 | 6 | 0.160 |
Why?
|
Financing, Government | 1 | 2019 | 7 | 0.160 |
Why?
|
Second-Look Surgery | 1 | 2019 | 4 | 0.160 |
Why?
|
Radiation Injuries | 2 | 2018 | 52 | 0.160 |
Why?
|
Arteriovenous Fistula | 1 | 2019 | 16 | 0.160 |
Why?
|
Melphalan | 1 | 2019 | 7 | 0.160 |
Why?
|
Lymph Nodes | 1 | 2020 | 103 | 0.160 |
Why?
|
Intracranial Arteriovenous Malformations | 1 | 2019 | 16 | 0.160 |
Why?
|
Salvage Therapy | 1 | 2019 | 34 | 0.160 |
Why?
|
Gadolinium | 1 | 2019 | 6 | 0.160 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 107 | 0.160 |
Why?
|
Mice | 7 | 2021 | 4621 | 0.160 |
Why?
|
Cell Cycle Checkpoints | 1 | 2019 | 30 | 0.160 |
Why?
|
Brain | 3 | 2018 | 739 | 0.160 |
Why?
|
Adolescent | 3 | 2021 | 3104 | 0.160 |
Why?
|
Photons | 1 | 2018 | 27 | 0.150 |
Why?
|
Cavernous Sinus | 1 | 2018 | 5 | 0.150 |
Why?
|
Brain Diseases | 1 | 2018 | 35 | 0.150 |
Why?
|
Peptides | 2 | 2013 | 287 | 0.150 |
Why?
|
Radio Waves | 1 | 2018 | 21 | 0.150 |
Why?
|
Electromagnetic Fields | 1 | 2018 | 14 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2013 | 103 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 20 | 0.150 |
Why?
|
Proton Therapy | 1 | 2018 | 29 | 0.150 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2019 | 42 | 0.150 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2018 | 26 | 0.150 |
Why?
|
Hobbies | 1 | 2018 | 1 | 0.150 |
Why?
|
Pacemaker, Artificial | 1 | 2018 | 55 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2018 | 14 | 0.150 |
Why?
|
Cranial Irradiation | 1 | 2018 | 12 | 0.150 |
Why?
|
Health Surveys | 1 | 2018 | 82 | 0.150 |
Why?
|
Organ Specificity | 1 | 2018 | 82 | 0.150 |
Why?
|
Academic Medical Centers | 1 | 2018 | 75 | 0.150 |
Why?
|
Tumor Cells, Cultured | 3 | 2003 | 315 | 0.150 |
Why?
|
Electric Stimulation Therapy | 1 | 2018 | 56 | 0.150 |
Why?
|
Infertility, Male | 1 | 2018 | 23 | 0.140 |
Why?
|
Postoperative Complications | 2 | 2021 | 611 | 0.140 |
Why?
|
Palliative Medicine | 1 | 2017 | 1 | 0.140 |
Why?
|
Particle Accelerators | 1 | 2017 | 5 | 0.140 |
Why?
|
Oregon | 1 | 2017 | 8 | 0.140 |
Why?
|
Infant | 1 | 2021 | 987 | 0.140 |
Why?
|
Fertility | 1 | 2018 | 58 | 0.140 |
Why?
|
Neoplasm Invasiveness | 2 | 2021 | 188 | 0.140 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 40 | 0.140 |
Why?
|
Bias | 1 | 2017 | 42 | 0.140 |
Why?
|
Time-to-Treatment | 1 | 2017 | 27 | 0.140 |
Why?
|
Young Adult | 3 | 2019 | 2714 | 0.140 |
Why?
|
Propensity Score | 1 | 2017 | 54 | 0.140 |
Why?
|
Recombinant Proteins | 2 | 2012 | 412 | 0.140 |
Why?
|
Postoperative Period | 1 | 2017 | 67 | 0.140 |
Why?
|
Immunotherapy | 1 | 2019 | 159 | 0.140 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 54 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2003 | 604 | 0.140 |
Why?
|
Hemangioblastoma | 1 | 2017 | 13 | 0.130 |
Why?
|
Odds Ratio | 1 | 2017 | 236 | 0.130 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 138 | 0.130 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 284 | 0.130 |
Why?
|
DNA Fragmentation | 2 | 2015 | 17 | 0.130 |
Why?
|
Prostatectomy | 3 | 2017 | 83 | 0.130 |
Why?
|
DNA, Neoplasm | 2 | 2009 | 34 | 0.130 |
Why?
|
Postoperative Care | 1 | 2016 | 68 | 0.130 |
Why?
|
Comorbidity | 1 | 2017 | 257 | 0.130 |
Why?
|
Protein Array Analysis | 2 | 2013 | 18 | 0.130 |
Why?
|
Sex Factors | 1 | 2018 | 465 | 0.130 |
Why?
|
Logistic Models | 1 | 2017 | 407 | 0.130 |
Why?
|
Head and Neck Neoplasms | 2 | 2009 | 87 | 0.130 |
Why?
|
Aged, 80 and over | 3 | 2021 | 2015 | 0.120 |
Why?
|
Survival Analysis | 2 | 2014 | 287 | 0.120 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2018 | 268 | 0.120 |
Why?
|
Cells, Cultured | 3 | 2021 | 984 | 0.120 |
Why?
|
Heptanoic Acids | 1 | 2015 | 1 | 0.120 |
Why?
|
Lanosterol | 1 | 2015 | 1 | 0.120 |
Why?
|
Catechols | 1 | 2015 | 2 | 0.120 |
Why?
|
Fatty Alcohols | 1 | 2015 | 4 | 0.120 |
Why?
|
Limonins | 1 | 2015 | 3 | 0.120 |
Why?
|
Flavones | 1 | 2015 | 3 | 0.120 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 112 | 0.120 |
Why?
|
Triterpenes | 1 | 2015 | 9 | 0.120 |
Why?
|
Immunoprecipitation | 1 | 2015 | 68 | 0.120 |
Why?
|
Sesquiterpenes | 1 | 2015 | 22 | 0.120 |
Why?
|
Models, Genetic | 2 | 2012 | 125 | 0.120 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 134 | 0.120 |
Why?
|
Prospective Studies | 1 | 2018 | 1244 | 0.120 |
Why?
|
Flow Cytometry | 1 | 2015 | 287 | 0.110 |
Why?
|
Transfection | 3 | 2005 | 317 | 0.110 |
Why?
|
Oxidative Stress | 1 | 2018 | 667 | 0.110 |
Why?
|
Phospholipases A2, Cytosolic | 1 | 2013 | 1 | 0.110 |
Why?
|
Benzoates | 1 | 2013 | 30 | 0.110 |
Why?
|
Receptors, Peptide | 1 | 2013 | 20 | 0.100 |
Why?
|
Protein Interaction Mapping | 1 | 2013 | 34 | 0.100 |
Why?
|
Peptide Library | 1 | 2013 | 26 | 0.100 |
Why?
|
Sulfonamides | 1 | 2013 | 73 | 0.100 |
Why?
|
Lentivirus | 1 | 2012 | 16 | 0.100 |
Why?
|
Enzyme Activation | 2 | 2003 | 267 | 0.100 |
Why?
|
Receptor, trkA | 1 | 2012 | 10 | 0.100 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 540 | 0.100 |
Why?
|
Radiation Tolerance | 1 | 2012 | 28 | 0.100 |
Why?
|
HEK293 Cells | 1 | 2012 | 186 | 0.100 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2012 | 64 | 0.090 |
Why?
|
Expert Testimony | 1 | 2011 | 7 | 0.090 |
Why?
|
Genotype | 2 | 2010 | 456 | 0.090 |
Why?
|
Unnecessary Procedures | 1 | 2011 | 7 | 0.090 |
Why?
|
Mastectomy | 1 | 2011 | 21 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 381 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2008 | 82 | 0.090 |
Why?
|
RNA, Messenger | 1 | 2012 | 657 | 0.080 |
Why?
|
Phenotype | 1 | 2012 | 680 | 0.080 |
Why?
|
Cell Death | 2 | 2007 | 118 | 0.080 |
Why?
|
ErbB Receptors | 1 | 2010 | 100 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 473 | 0.080 |
Why?
|
Hypothyroidism | 1 | 2009 | 11 | 0.080 |
Why?
|
Thyroid Gland | 1 | 2009 | 32 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2010 | 391 | 0.080 |
Why?
|
Cell Survival | 3 | 2018 | 408 | 0.080 |
Why?
|
Phagosomes | 1 | 2009 | 6 | 0.080 |
Why?
|
Necrosis | 1 | 2009 | 83 | 0.080 |
Why?
|
Capsid | 1 | 2009 | 12 | 0.080 |
Why?
|
In Situ Nick-End Labeling | 1 | 2009 | 42 | 0.080 |
Why?
|
Contrast Media | 2 | 2020 | 95 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 68 | 0.080 |
Why?
|
Bacteriophage T7 | 1 | 2009 | 7 | 0.080 |
Why?
|
Adenoviridae | 1 | 2009 | 67 | 0.080 |
Why?
|
Cloning, Molecular | 1 | 2009 | 205 | 0.080 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 268 | 0.080 |
Why?
|
Caspase Inhibitors | 1 | 2008 | 8 | 0.070 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2009 | 74 | 0.070 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 163 | 0.070 |
Why?
|
Paclitaxel | 2 | 2009 | 190 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 113 | 0.070 |
Why?
|
Liposomes | 1 | 2009 | 145 | 0.070 |
Why?
|
Immunohistochemistry | 1 | 2009 | 461 | 0.070 |
Why?
|
Amino Acid Sequence | 1 | 2009 | 687 | 0.070 |
Why?
|
Up-Regulation | 1 | 2008 | 246 | 0.070 |
Why?
|
Chromones | 2 | 2005 | 11 | 0.070 |
Why?
|
Morpholines | 2 | 2005 | 28 | 0.070 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 1048 | 0.070 |
Why?
|
Biomarkers, Tumor | 2 | 2021 | 404 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 242 | 0.070 |
Why?
|
Macrophages | 2 | 2020 | 292 | 0.070 |
Why?
|
Mice, Nude | 2 | 2008 | 330 | 0.060 |
Why?
|
Mice, SCID | 2 | 2002 | 60 | 0.060 |
Why?
|
Canada | 1 | 2025 | 60 | 0.060 |
Why?
|
Amifostine | 1 | 2004 | 5 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2005 | 166 | 0.060 |
Why?
|
Mucous Membrane | 1 | 2004 | 28 | 0.060 |
Why?
|
Quality of Life | 2 | 2018 | 484 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 1 | 2005 | 140 | 0.060 |
Why?
|
Algorithms | 2 | 2020 | 430 | 0.050 |
Why?
|
Precipitin Tests | 1 | 2003 | 47 | 0.050 |
Why?
|
Pilot Projects | 1 | 2025 | 430 | 0.050 |
Why?
|
Vinblastine | 1 | 2002 | 6 | 0.050 |
Why?
|
Tetracycline | 1 | 2002 | 4 | 0.050 |
Why?
|
Etoposide | 1 | 2002 | 19 | 0.050 |
Why?
|
Acetylation | 1 | 2002 | 36 | 0.050 |
Why?
|
Incidental Findings | 1 | 2022 | 13 | 0.050 |
Why?
|
Doxorubicin | 1 | 2002 | 77 | 0.050 |
Why?
|
Histones | 1 | 2002 | 92 | 0.050 |
Why?
|
Hospitals, Community | 1 | 2021 | 8 | 0.050 |
Why?
|
Age Factors | 2 | 2018 | 733 | 0.050 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2002 | 15 | 0.050 |
Why?
|
Transplantation, Heterologous | 1 | 2002 | 60 | 0.050 |
Why?
|
Central Nervous System | 1 | 2021 | 37 | 0.050 |
Why?
|
PubMed | 1 | 2021 | 8 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2002 | 343 | 0.040 |
Why?
|
Time Factors | 2 | 2018 | 1590 | 0.040 |
Why?
|
Proof of Concept Study | 1 | 2020 | 12 | 0.040 |
Why?
|
Neuroimaging | 1 | 2020 | 87 | 0.040 |
Why?
|
Artifacts | 1 | 2020 | 50 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 610 | 0.040 |
Why?
|
Embolization, Therapeutic | 1 | 2019 | 46 | 0.040 |
Why?
|
Rats | 1 | 2002 | 1570 | 0.040 |
Why?
|
Magnetite Nanoparticles | 1 | 2019 | 16 | 0.040 |
Why?
|
Incidence | 1 | 2020 | 562 | 0.040 |
Why?
|
Preliminary Data | 1 | 2018 | 4 | 0.040 |
Why?
|
Endovascular Procedures | 1 | 2019 | 69 | 0.040 |
Why?
|
Cell Fusion | 1 | 2018 | 7 | 0.040 |
Why?
|
Karyotyping | 1 | 2018 | 25 | 0.040 |
Why?
|
Transportation of Patients | 1 | 2018 | 29 | 0.040 |
Why?
|
Protons | 1 | 2018 | 54 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2018 | 101 | 0.040 |
Why?
|
Memantine | 1 | 2018 | 2 | 0.040 |
Why?
|
Cell Line | 2 | 2012 | 695 | 0.040 |
Why?
|
Orchiectomy | 1 | 2018 | 12 | 0.040 |
Why?
|
Scandinavian and Nordic Countries | 1 | 2017 | 2 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2018 | 96 | 0.040 |
Why?
|
Cryopreservation | 1 | 2018 | 13 | 0.040 |
Why?
|
Neuroprotective Agents | 1 | 2018 | 52 | 0.040 |
Why?
|
Registries | 1 | 2020 | 387 | 0.040 |
Why?
|
Phosphorylation | 2 | 2012 | 574 | 0.040 |
Why?
|
Risk | 1 | 2017 | 136 | 0.040 |
Why?
|
Disease Management | 1 | 2018 | 88 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2018 | 118 | 0.030 |
Why?
|
Length of Stay | 1 | 2018 | 228 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2018 | 507 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2018 | 247 | 0.030 |
Why?
|
Disease Progression | 1 | 2018 | 472 | 0.030 |
Why?
|
Cognition Disorders | 1 | 2018 | 184 | 0.030 |
Why?
|
Health Promotion | 1 | 2017 | 176 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2013 | 1454 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 293 | 0.030 |
Why?
|
Glycogen Synthase Kinase 3 beta | 1 | 2015 | 41 | 0.030 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2015 | 31 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2015 | 56 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2013 | 25 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 1561 | 0.030 |
Why?
|
Drug Discovery | 1 | 2013 | 34 | 0.030 |
Why?
|
Xanthones | 1 | 2012 | 6 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2012 | 53 | 0.020 |
Why?
|
DNA Repair | 1 | 2012 | 82 | 0.020 |
Why?
|
Automation | 1 | 2011 | 19 | 0.020 |
Why?
|
Community Health Services | 1 | 2011 | 32 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2013 | 350 | 0.020 |
Why?
|
Mammography | 1 | 2011 | 79 | 0.020 |
Why?
|
Bridged-Ring Compounds | 1 | 2009 | 18 | 0.020 |
Why?
|
Taxoids | 1 | 2009 | 37 | 0.020 |
Why?
|
Haplotypes | 1 | 2010 | 283 | 0.020 |
Why?
|
Radiography | 1 | 2009 | 202 | 0.020 |
Why?
|
Everolimus | 1 | 2008 | 16 | 0.020 |
Why?
|
Caspase 3 | 1 | 2008 | 57 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 156 | 0.020 |
Why?
|
Models, Biological | 1 | 2009 | 466 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 223 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2005 | 155 | 0.010 |
Why?
|
Risk Factors | 1 | 2009 | 2078 | 0.010 |
Why?
|
Genes, myc | 1 | 2002 | 9 | 0.010 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2002 | 15 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2002 | 66 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 154 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2002 | 160 | 0.010 |
Why?
|